Swiss Chems Provider Profile Name: Swiss Chems Website: swisschems.com Founded: August 2018 Provider Type: Research Peptide Vendor FDA Warning Letter: December 10, 2024 Operating Details E-commerce peptide vendor Received an FDA warning letter in December 2024 after an investigation found the company was selling semaglutide and retatrutide products for human use despite marketing them for research and chemical purposes No prescription required for purchase Products sold as freeze-dried powders requiring reconstitution About the Company Swiss Chems was among the companies targeted in the FDAs December 2024 enforcement wave, alongside Xcel Peptides, Summit Research, and Prime Peptides, all found to be selling semaglutide, tirzepatide, and/or retatrutide for human use despite marketing the drugs for research and chemical purposes
You never want to feel stuck in a situation where you feel like your adjustment period is difficult and you have no one to talk to
PlexusDx offers compounded semaglutide injections at $189/mo month-to-month, or from $149/mo on the 6-month plan, flat pricing regardless of dose strength
Another way to think about this is that TrimRX's screen is broad enough to catch many obvious GLP-1 contraindications, but Hims is more explicit in how it handles edge cases that can matter in telehealth prescribing
"I feel privileged to have access to a GLP-1 and I think everybody should, through insurance
In some embodiments, the formulations described herein have a pH and/or practical osmolarity as described herein, and have a concentration of active pharmaceutical ingredient from about 0.0001% to about 60%, from about 0.001% to about 40%, from about 0.01% to about 20%, from about 0.01% to about 10%, from about 0.01% to about 7.5%, from about 0.01% to about 6%, from about 0.01 to about 5%, from about 0.1 to about 10%, or from about 0.1 to about 6% of the active ingredient by weight of the formulation
